Low-Dose Aspirin for PI3K-Altered Colorectal Cancer
“`html
RSV Vaccine Approved for Older Adults: A Breakthrough in respiratory Protection
Understanding RSV and Why it’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Before the availability of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the United States.
The virus spreads through close contact with infected individuals, often via respiratory droplets produced during coughing or sneezing. Older adults are particularly vulnerable due to age-related decline in immune function and the presence of underlying health conditions like heart disease or chronic lung disease.
the Arexvy Vaccine: How It Works and Trial Results
Arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine triggers the production of antibodies that can neutralize the virus and prevent infection.
The pivotal Phase 3 trial, published in the New England Journal of Medicine on November 27, 2025, involved over 12,600 adults aged 60 years and older. The results demonstrated a vaccine efficacy of 82.6% against RSV-associated lower respiratory tract disease (LRTD) – defined as having at least two symptoms including cough, shortness of breath, wheezing, or fever. The vaccine also showed efficacy against severe LRTD,with a 94.1% reduction in cases requiring hospitalization.
Importantly, the trial also assessed safety. While some participants experienced mild side effects such as pain at the injection site, fatigue, and muscle aches, serious adverse events were rare and not significantly different between the vaccine and placebo groups. A small number of participants experienced Guillain-Barré syndrome, a rare neurological disorder, but the causal relationship to the vaccine remains under examination.
Who Should Get the RSV Vaccine?
The FDA approved Arexvy for adults aged 60 years and older to help prevent RSV-associated LRTD. The Centers for Disease Control and Prevention (CDC) provides recommendations on who should receive the vaccine, taking into account individual health status and risk factors. Currently, the CDC recommends a shared clinical decision-making approach, meaning that individuals should discuss the benefits and risks of vaccination with their healthcare provider.
Factors that may influence the decision include:
- Age (60 years and older)
- Underlying health conditions (heart disease, lung disease, diabetes)
- lifestyle (close contact with young children)
- Previous RSV infections
Timeline of RSV Vaccine Growth
| Year | milestone |
|---|---|
| 2023 (May 3) | FDA approves Arexvy for adults 60+ |
| 2025 (November 27) |